Evaluation of Fructans Supplementation on Parameters of Metabolic Syndrome
NCT ID: NCT00616057
Last Updated: 2012-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
34 participants
INTERVENTIONAL
2008-02-29
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In our laboratory, we have demonstrated that the intake of fructans lessens dietary intake, body weight gain, adipose tissue accumulation and steatosis in rodents. These effects lead to an improvement of insulin resistance and hyperglycemia in diabetic rats and mice. Fructans are also able to restore the microflora disturbed by a high fat diet and to prevent endotoxemia. Moreover, studies have shown that fructans intake promotes satiety (Cani et al, Diabetes 2007) and or decreases fat mass (Abrams et al, Journal of Pediatrics 2007) in healthy human. An intervention study in obese patients is thus needed to study the effects of fructans in the target population.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
B
Maltodextrin, non digestible carbohydrate
maltodextrin
8 grams/day during the first week and then 8 grams twice a day during 3 months
A
fructans, non digestible carbohydrates fermented in the caeco-colon
Synergy 1
8 grams/day during the first week and then 8 grams twice a day during 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Synergy 1
8 grams/day during the first week and then 8 grams twice a day during 3 months
maltodextrin
8 grams/day during the first week and then 8 grams twice a day during 3 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* alcohol consumption \> 30 units/week
* more than 30 minutes of sports 3 times/week
* usual consumption of pre/probiotics or fibers supplement
* recent consumption of antibiotics
* slimming diet or unusual diet
* pregnant women
* anti-diabetics drugs ou slimming drugs
* previous bariatric surgery
* severe oesophagus reflux
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thissen Jean-Paul
Role: PRINCIPAL_INVESTIGATOR
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cliniques universitaires Saint Luc
Brussels, Branbant Wallon, Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Salazar N, Dewulf EM, Neyrinck AM, Bindels LB, Cani PD, Mahillon J, de Vos WM, Thissen JP, Gueimonde M, de Los Reyes-Gavilan CG, Delzenne NM. Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women. Clin Nutr. 2015 Jun;34(3):501-7. doi: 10.1016/j.clnu.2014.06.001. Epub 2014 Jun 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B40320072930
Identifier Type: -
Identifier Source: secondary_id
2007/21/NOV/300
Identifier Type: -
Identifier Source: org_study_id